Treatment options in paraneoplastic disorders of the peripheral nervous system

Current Treatment Options in Neurology

Volumn 15, Issue 2, 2013, Pages 210-223

  Antoine, Jean Christophe ^a,b,c   Camdessanché, Jean Philippe ^a,b,c  

^a UNIVERSITY HOSPITAL OF SAINT ETIENNE   (France)

^b French Reference Center for Paraneoplastic Neurological Syndrome   (France)

^c 'Rhône Alpes Reference Center for Rare Neuromuscular Diseases   (France)

Author keywords

3 4 diaminopyridine; Cyclophosphamide; Intravenous immunoglobulins; Lambert Eaton myasthenic syndrome; Paraneoplastic neurological syndrome; Peripheral nerve hyperexcitability; Peripheral nervous system; Peripheral neuropathy; Plasma exchange; Rituximab; Subacute sensory neuronopathy; Treatment

Indexed keywords

3,4 DIAMINOPYRIDINE; AMITRIPTYLINE; CARBAMAZEPINE; CELL ANTIGEN; COLLAPSIN RESPONSE MEDIATOR PROTEIN; CYCLOPHOSPHAMIDE; DULOXETINE; GABAPENTIN; HUD PROTEIN; IMMUNOGLOBULIN; METHYLPREDNISOLONE; NUCLEIC ACID BINDING PROTEIN; PREGABALIN; PROTEIN CRMP5; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG; VENLAFAXINE;

ACNE; ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ALOPECIA; AMENORRHEA; ANEMIA; ANGIONEUROTIC EDEMA; ANXIETY; ARTERY THROMBOSIS; ASEPTIC MENINGITIS; AZOOSPERMIA; BACKACHE; BLOOD TOXICITY; BLURRED VISION; BRONCHOSPASM; CARDIOGENIC SHOCK; CARDIOVASCULAR EFFECT; CATHETER INFECTION; CONCENTRATION LOSS; CONFUSION; CONGENITAL MALFORMATION; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEPRESSION; DIARRHEA; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG FATALITY; DRUG FEVER; DRUG HYPERSENSITIVITY; DRUG INDICATION; DRUG RESPONSE; DRUG SAFETY; DYSARTHRIA; DYSURIA; ECZEMA; EDEMA; EPIGASTRIC DISCOMFORT; EUPHORIA; EYE DISEASE; FATIGUE; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEART VENTRICLE FIBRILLATION; HEARTBURN; HEMATOMA; HEMOLYTIC ANEMIA; HEMORRHAGIC CYSTITIS; HUMAN; HYPERGLYCEMIA; HYPERHIDROSIS; HYPERTENSION; HYPERTRANSAMINASEMIA; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOTENSION; HYPOXIA; INSOMNIA; LIVER TOXICITY; LUNG INFILTRATE; LYMPHOCYTOPENIA; MANIA; MEMORY DISORDER; MYALGIA; NAUSEA; NEUROPATHIC PAIN; NEUTROPENIA; PARANEOPLASTIC NEUROPATHY; PARESTHESIA; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PULMONARY HYPERTENSION; REVIEW; SEIZURE; SEXUAL DYSFUNCTION; SHIVERING; SIDE EFFECT; SKIN DISCOLORATION; SKIN MANIFESTATION; SKIN TINGLING; SOMNOLENCE; SPONTANEOUS ABORTION; STOMACH ULCER; SUICIDE; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMIC LUPUS ERYTHEMATOSUS; TACHYCARDIA; THORAX PAIN; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TOXIC HEPATITIS; TREATMENT PLANNING; TREMOR; TUMOR LYSIS SYNDROME; UNSTEADINESS; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 84877603800     PISSN: 10928480     EISSN: 15343138     Source Type: Journal    
DOI: 10.1007/s11940-012-0210-9     Document Type: Review

References (63)

1. Antoine JC, Camdessanche JP. Peripheral nervous system involvement in patients with cancer. Lancet Neurol. 2007;6(1):75-86.
2. Graus F, Delattre JY, Antoine JC, Dalmau J, Giometto B, Grisold W, et al. Recommended diagnostic criteria for paraneoplastic neurological syndromes. J Neurol Neurosurg Psychiatry. 2004;75(8):1135-40.
3. Giometto B, Grisold W, Vitaliani R, Graus F, Honnorat J, Bertolini G. Paraneoplastic neurologic syndrome in the PNS euronetwork database: a European study from 20 centers. Arch Neurol. 2010;67(3):330-5.
4. Benyahia B, Liblau R, Merle-Beral H, Tourani JM, Dalmau J, Delattre JY. Cell-mediated autoimmunity in paraneoplastic neurological syndromes with anti-Hu antibodies. Ann Neurol. 1999;45(2):162-7.
5. Darnell RB, Posner JB. Observing the invisible: successful tumor immunity in humans. Nat Immunol. 2003;4(3):201.
6. Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011;77(2):179-89.
7. Honnorat J, Viaccoz A. New concepts in paraneoplastic neurological syndromes. Rev Neurol (Paris). 2011;167(10):729-36.
8. Zuliani L, Graus F, Giometto B, Bien C, Vincent A. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83(6):638-45.
9. Szabo A, Dalmau J, Manley G, Rosenfeld M, Wong E, Henson J, et al. HuD, a paraneoplastic encephalomyelitis antigen, contains RNA-binding domains and is homologous to elav and sex-lethal. Cell. 1991;67(2):325-33.
10. Camdessanche JP, Jousserand G, Ferraud K, Vial C, Petiot P, Honnorat J, et al. The pattern and diagnostic criteria of sensory neuronopathy: a case-control study. Brain. 2009;132(Pt 7):1723-33.
11. Camdessanche JP, Jousserand G, Franques J, Pouget J, Delmont E, Creange A, et al. A clinical pattern-based etiological diagnostic strategy for sensory neuronopathies: a French collaborative study. J Peripher Nerv Syst. 2012;17(3):331-40. This paper provides a controlled strategy for the etiological diagnosis of sensory neuronopathy identified by the diagnosis criteria published in reference 10 allowing distinguishing paraneoplastic from non paraneoplastic forms.
12. Graus F, Keime-Guibert F, Rene R, Benyahia B, Ribalta T, Ascaso C, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain. 2001;124(Pt 6):1138-48.
13. Camdessanche JP, Ferraud K, Boutahar N, Lassabliere F, Mutter M, Touret M, et al. The collapsin response mediator protein 5 onconeural protein is expressed in Schwann cells under axonal signals and regulates axon-Schwann cell interactions. J Neuropathol Exp Neurol. 2012;71(4):298-311.
14. Honnorat J, Cartalat-Carel S, Ricard D, Camdessanche JP, Carpentier AF, Rogemond V, et al. Onco-neural antibodies and tumour type determine survival and neurological symptoms in paraneoplastic neurological syndromes with Hu or CV2/CRMP5 antibodies. J Neurol Neurosurg Psychiatry. 2009;80(4):412-6.
15. Vincent A, Lang B, Newsom-Davis J. Autoimmunity to the voltage-gated calcium channel underlies the lambert-Eaton myasthenic syndrome, a paraneoplastic disorder. Trends Neurosci. 1989;12(12):496-502.
16. O'Neill JH, Murray NM, Newsom-Davis J. The lambert-aton myasthenic syndrome. A review of 50 cases. Brain. 1988;111(Pt 3):577-96.
17. Wirtz PW, Smallegange TM, Wintzen AR, Verschuuren JJ. Differences in clinical features between the lambert-Eaton myasthenic syndrome with and without cancer: an analysis of 227 published cases. Clin Neurol Neurosurg. 2002;104(4):359-63.
18. Lennon VA, Kryzer TJ, Griesmann GE, O'Suilleabhain PE, Windebank AJ, Woppmann A, et al. Calcium-channel antibodies in the lambert-Eaton syndrome and other paraneoplastic syndromes. N Engl J Med. 1995;332(22):1467-74.
19. Takamori M, Iwasa K, Komai K. Antibodies to synthetic peptides of the alpha1a subunit of the voltage-gated calcium channel in lambert-Eaton myasthenic syndrome. Neurology. 1997;48(5):1261-5.
20. Motomura M, Lang B, Johnston I, Palace J, Vincent A, Newsom-Davis J. Incidence of serum anti-P/O-type and anti-N-type calcium channel autoantibodies in the lambert-eaton myasthenic syndrome. J Neurol Sci. 1997;147(1):35-42.
21. Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO, Graus F. Sox1 antibodies are markers of paraneoplastic lambert-Eaton myasthenic syndrome. Neurology. 2008;70(12):924-8.
22. Titulaer MJ, Klooster R, Potman M, Sabater L, Graus F, Hegeman IM, et al. Sox 1 antibodies in small-cell lung cancer and lambert-Eaton myasthenic syndrome: frequency and relation with survival. J Clin Oncol. 2009;27(26):4260-7.
23. Clouston PD, Saper CB, Arbizu T, Johnston I, Lang B, Newsom-Davis J, et al. Paraneoplastic cerebellar degeneration. Iii. Cerebellar degeneration, cancer, and the lambert-Eaton myasthenic syndrome. Neurology. 1992;42(10):1944-50.
24. Vincent A, Irani SR. Caspr2 antibodies in patients with thymomas. J Thorac Oncol. 2010;5(10 Suppl 4):S277-80.
25. Lancaster E, Huijbers MG, Bar V, Boronat A, Wong A, Martinez-Hernandez E, et al. Investigations of caspr2, an autoantigen of encephalitis and neuromyotonia. Ann Neurol. 2011;69(2):303-11. This paper identifies CASPR 2 as the main target of antibodies in neuromyotonia.
26. Panzer J, Dalmau J. Movement disorders in paraneoplastic and autoimmune disease. Curr Opin Neurol. 2011;24(4):346-53.
27. Hart IK, Maddison P, Newsom-Davis J, Vincent A, Mills KR. Phenotypic variants of autoimmune peripheral nerve hyperexcitability. Brain. 2002;125(Pt 8):1887-95.
28. Shillito P, Molenaar PC, Vincent A, Leys K, Zheng W, van den Berg RJ, et al. Acquired neuromyotonia: evidence for autoantibodies directed against k+ channels of peripheral nerves. Ann Neurol. 1995;38(5):714-22.
29. Arimura K, Watanabe O, Kitajima I, Suehara M, Minato S, Sonoda Y, et al. Antibodies to potassium channels of pc12 in serum of Isaacs' syndrome: Western blot and immunohistochemical studies. Muscle Nerve. 1997;20(3):299-305.
30. Irani SR, Alexander S, Waters P, Kleopa KA, Pettingill P, Zuliani L, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan's syndrome and acquired neuromyotonia. Brain. 2010;133(9):2734-48.
31. Irani SR, Pettingill P, Kleopa KA, Schiza N, Waters P, Mazia C, et al. Morvan syndrome: clinical and serological observations in 29 cases. Ann Neurol. 2012;72(2):241-55. An important study on the rare Morvan syndrome.
32. Lai M, Huijbers MG, Lancaster E, Graus F, Bataller L, Balice-Gordon R, et al. Investigation of Lgi1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9(8):776-85. This paper identifies LGI1 as the actual target of antibodies in a subgroup of patients with limbic encephalitis.
33. Keime-Guibert F, Graus F, Broet P, Rene R, Molinuevo JL, Ascaso C, et al. Clinical outcome of patients with anti-Hu-associated encephalomyelitis after treatment of the tumor. Neurology. 1999;53(8):1719-23.
34. Vedeler CA, Antoine JC, Giometto B, Graus F, Grisold W, Hart IK, et al. Management of paraneoplastic neurological syndromes: report of an EFNS task force. Eur J Neurol. 2006;13(7):682-90.
35. Psimaras D, Carpentier AF, Rossi C. CSF study in paraneoplastic syndromes. J Neurol Neurosurg Psychiatry. 2010;81(1):42-5.
36. Titulaer MJ, Soffietti R, Dalmau J, Gilhus NE, Giometto B, Graus F, et al. Screening for tumours in paraneoplastic syndromes: report of an EFNS task force. Eur J Neurol. 2011;18(1):19-e13. This paper provides recommendation on the best strategy to develop to obtain an early diagnosis of the cancer.
37. Uchuya M, Graus F, Vega F, Rene R, Delattre JY. Intravenous immunoglobulin treatment in paraneoplastic neurological syndromes with antineuronal autoantibodies. J Neurol Neurosurg Psychiatry. 1996;60(4):388-92.
38. Graus F, Vega F, Delattre JY, Bonaventura I, Rene R, Arbaiza D, et al. Plasmapheresis and antineoplastic treatment in CNS paraneoplastic syndromes with antineuronal autoantibodies. Neurology. 1992;42(3 Pt 1):536-40.
39. Stark E, Wurster U, Patzold U, Sailer M, Haas J. Immunological and clinical response to immunosuppressive treatment in paraneoplastic cerebellar degeneration. Arch Neurol. 1995;52(8):814-8.
40. Albert ML, Austin LM, Darnell RB. Detection and treatment of activated t cells in the cerebrospinal fluid of patients with paraneoplastic cerebellar degeneration. Ann Neurol. 2000;47(1):9-17.
41. Shams'ili S, de Beukelaar J, Gratama JW, Hooijkaas H, van den Bent M, Van't Veer M, et al. An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. J Neurol. 2006;253(1):16-20.
42. Keime-Guibert F, Graus F, Fleury A, Rene R, Honnorat J, Broet P, et al. Treatment of paraneoplastic neurological syndromes with antineuronal antibodies (anti-Hu, anti-Yo) with a combination of immunoglobulins, cyclophosphamide, and methylprednisolone. J Neurol Neurosurg Psychiatry. 2000;68(4):479-82.
43. Vernino S, O'Neill BP, Marks RS, O'Fallon JR, Kimmel DW. Immunomodulatory treatment trial for paraneoplastic neurological disorders. Neuro Oncol. 2004;6(1):55-62.
44. Bain PG, Motomura M, Newsom-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effects of intravenous immunoglobulin on muscle weakness and calcium-channel autoantibodies in the lambert-Eaton myasthenic syndrome. Neurology. 1996;47(3):678-83.
45. Newsom-Davis J, Murray N, Wray D, Lang B, Prior C, Gwilt M, et al. Lambert-Eaton myasthenic syndrome: electrophysiological evidence for a humoral factor. Muscle Nerve. 1982;5(9S):S17-20.
46. Maddison P, McConville J, Farrugia ME, Davies N, Rose M, Norwood F, et al. The use of rituximab in myasthenia gravis and lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry. 2011;82(6):671-3.
47. Attal N, Cruccu G, Baron R, Haanpaa M, Hansson P, Jensen TS, et al. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17(9):1113-e1188. An interesting review of the different treatment of neuropathic pain with guidelines.
48. McEvoy KM, Windebank AJ, Daube JR, Low PA. 3,4-diaminopyridine in the treatment of lambert-Eaton myasthenic syndrome. N Engl J Med. 1989;321(23):1567-71.
49. Oh SJ, Claussen GG, Hatanaka Y, Morgan MB. 3,4-diaminopyridine is more effective than placebo in a randomized, double-blind, cross-over drug study in LEMS. Muscle Nerve. 2009;40(5):795-800.
50. Sanders DB, Massey JM, Sanders LL, Edwards LJ. A randomized trial of 3,4-diaminopyridine in lambert-Eaton myasthenic syndrome. Neurology. 2000;54(3):603-7.
51. Wirtz PW, Verschuuren JJ, van Dijk JG, de Kam ML, Schoemaker RC, van Hasselt JG, et al. Efficacy of 3,4-diaminopyridine and pyridostigmine in the treatment of lambert-Eaton myasthenic syndrome: a randomized, double-blind, placebo-controlled, crossover study. Clin Pharmacol Ther. 2009;86(1):44-8.
52. Keogh M, Sedehizadeh S, Maddison P. Treatment for lambert-Eaton myasthenic syndrome. Cochrane Database Syst Rev. 2011;2:CD003279. An excellent review of the available evidence for the treatment of LEMS completed with a meta-analysis.
53. Skeie GO, Apostolski S, Evoli A, Gilhus NE, Illa I, Harms L, et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur J Neurol. 2010;17(7):893-902. This paper provides guidelines for the management of LEMS and PNH.
54. Elovaara I, Apostolski S, van Doorn P, Gilhus NE, Hietaharju A, Honkaniemi J, et al. EFNS guidelines for the use of intravenous immunoglobulin in treatment of neurological diseases: efns task force on the use of intravenous immunoglobulin in treatment of neurological diseases. Eur J Neurol. 2008;15(9):893-908.
55. Dalakas MC. Invited article: inhibition of B cell functions: implications for Neurology. Neurology. 2008;70(23):2252-60.
56. Ramos-Casals M, Sanz I, Bosch X, Stone JH, Khamashta MA. B-cell-depleting therapy in systemic lupus erythematosus. Am J Med. 2012;125(4):327-36.
57. Tavazzi E, Ferrante P, Khalili K. Progressive multifocal leukoencephalopathy: an unexpected complication of modern therapeutic monoclonal antibody therapies. Clin Microbiol Infect. 2011;17(12):1776-80.
58. Dalmau J, Lancaster E, Martinez-Hernandez E, Rosenfeld MR, Balice-Gordon R. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10(1):63-74.
59. Graus F, Dalmau J. Paraneoplastic neurological syndromes: diagnosis and treatment. Curr Opin Neurol. 2007;20(6):732-7.
60. O'Connor AB. Neuropathic pain: quality-of-life impact, costs and cost effectiveness of therapy. Pharmacoeconomics. 2009;27(2):95-112.
61. Hughes RA. Give or take? Intravenous immunoglobulin or plasma exchange for Guillain-Barré syndrome. Crit Care. 2011;15(4):174.
62. Mehndiratta MM, Hughes RA. Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev. 2012;9:CD003906.
63. Gajdos P, Chevret S, Toyka K. Plasma exchange for myasthenia gravis. Cochrane Database Syst Rev. 2002;4:CD002275.